Skip to main navigation Skip to search Skip to main content

Rational design of antibody protease inhibitors

  • Tao Liu
  • , Guangsen Fu
  • , Xiaozhou Luo
  • , Yan Liu
  • , Ying Wang
  • , Rongsheng E. Wang
  • , Peter G. Schultz*
  • , Feng Wang
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The bovine antibody BLV1H12, which has an ultralong CDR3H, provides a novel scaffold for engineering new functions into the antibody's variable region. By modifying the β-strand "stalk" of BLV1H12 with sequences derived from natural or synthetic protease inhibitors, we have generated antibodies that inhibit bovine trypsin and human neutrophil elastase (HNE) with low nanomolar affinities. We were also able to generate a humanized variant using a human immunoglobulin scaffold that shares a high degree of homology with BLV1H12. Further optimization yielded a highly selective humanized anti-HNE antibody with sub-nanomolar affinity. This work demonstrates a novel strategy for generating antibodies with potent and selective inhibitory activities against extracellular proteases involved in human disease.

Original languageEnglish
Pages (from-to)4042-4045
Number of pages4
JournalJournal of the American Chemical Society
Volume137
Issue number12
DOIs
StatePublished - 1 Apr 2015
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Rational design of antibody protease inhibitors'. Together they form a unique fingerprint.

Cite this